Abstract
Background: Recurrent or metastatic (R/M) skin squamous cell carcinoma (sSCC) not amenable of surgery or irradiation may benefit from systemic therapies. Epidermal growth factor receptor (EGFR) inhibitors and, more recently, immune checkpoint blockers (ICBs) showed activity in R/M sSCC. In this study, we aimed at exploring the possible role of PD-L1 expression in predicting response to anti-EGFR agents. Methods: Patients affected by R/M sSCC, treated with pan-HER inhibitor dacomitinib or with platinum-based chemotherapy with cetuximab (CT-cet) from 2010 to 2016, were considered. PD-L1 expression was assessed with immunohistochemistry on tumor cells (TCs) and on microenvironment (TC and tumor-infiltrating lymphocyte [IC] scores, respectively). Prognostic role of PD-L1 and the correlation with response to EGFR inhibitors and survival were analyzed. Results: Twenty-eight R/M sSCCs were analyzed (19 treated with dacomitinib, 9 with CT-cet). TC and IC were negative in 82 and 45% of cases, respectively; 15% sSCCs were both TC and IC positive. Progression-free survival (PFS) was longer in IC-positive cases (median 7.5 months vs. 2.1 in IC0, p = 0.02). No statistically significant differences were observed between PD-L1 expression and both overall survival and response rates. Conclusion: PD-L1 expression in microenvironment predicted better PFS. The combination of EGFR inhibitors and ICB could help deepening the knowledge about the interrelations between the EGFR and PD-1/PD-L1 pathways.
| Original language | English |
|---|---|
| Pages (from-to) | 112-118 |
| Number of pages | 7 |
| Journal | Oncology (Switzerland) |
| Volume | 97 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jul 1 2019 |
Fingerprint
Keywords
- Anti-epidermal growth factor receptor treatment
- Epidermal growth factor receptor
- Outcome
- PD-L1
- Skin squamous cell carcinoma
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. / Cavalieri, Stefano; Perrone, Federica; Milione, Massimo; Bianco, Alba; Alfieri, Salvatore; Locati, Laura D.; Bergamini, Cristiana; Resteghini, Carlo; Galbiati, Donata; Platini, Francesca; Licitra, Lisa; Bossi, Paolo.
In: Oncology (Switzerland), Vol. 97, No. 2, 01.07.2019, p. 112-118.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents
AU - Cavalieri, Stefano
AU - Perrone, Federica
AU - Milione, Massimo
AU - Bianco, Alba
AU - Alfieri, Salvatore
AU - Locati, Laura D.
AU - Bergamini, Cristiana
AU - Resteghini, Carlo
AU - Galbiati, Donata
AU - Platini, Francesca
AU - Licitra, Lisa
AU - Bossi, Paolo
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Background: Recurrent or metastatic (R/M) skin squamous cell carcinoma (sSCC) not amenable of surgery or irradiation may benefit from systemic therapies. Epidermal growth factor receptor (EGFR) inhibitors and, more recently, immune checkpoint blockers (ICBs) showed activity in R/M sSCC. In this study, we aimed at exploring the possible role of PD-L1 expression in predicting response to anti-EGFR agents. Methods: Patients affected by R/M sSCC, treated with pan-HER inhibitor dacomitinib or with platinum-based chemotherapy with cetuximab (CT-cet) from 2010 to 2016, were considered. PD-L1 expression was assessed with immunohistochemistry on tumor cells (TCs) and on microenvironment (TC and tumor-infiltrating lymphocyte [IC] scores, respectively). Prognostic role of PD-L1 and the correlation with response to EGFR inhibitors and survival were analyzed. Results: Twenty-eight R/M sSCCs were analyzed (19 treated with dacomitinib, 9 with CT-cet). TC and IC were negative in 82 and 45% of cases, respectively; 15% sSCCs were both TC and IC positive. Progression-free survival (PFS) was longer in IC-positive cases (median 7.5 months vs. 2.1 in IC0, p = 0.02). No statistically significant differences were observed between PD-L1 expression and both overall survival and response rates. Conclusion: PD-L1 expression in microenvironment predicted better PFS. The combination of EGFR inhibitors and ICB could help deepening the knowledge about the interrelations between the EGFR and PD-1/PD-L1 pathways.
AB - Background: Recurrent or metastatic (R/M) skin squamous cell carcinoma (sSCC) not amenable of surgery or irradiation may benefit from systemic therapies. Epidermal growth factor receptor (EGFR) inhibitors and, more recently, immune checkpoint blockers (ICBs) showed activity in R/M sSCC. In this study, we aimed at exploring the possible role of PD-L1 expression in predicting response to anti-EGFR agents. Methods: Patients affected by R/M sSCC, treated with pan-HER inhibitor dacomitinib or with platinum-based chemotherapy with cetuximab (CT-cet) from 2010 to 2016, were considered. PD-L1 expression was assessed with immunohistochemistry on tumor cells (TCs) and on microenvironment (TC and tumor-infiltrating lymphocyte [IC] scores, respectively). Prognostic role of PD-L1 and the correlation with response to EGFR inhibitors and survival were analyzed. Results: Twenty-eight R/M sSCCs were analyzed (19 treated with dacomitinib, 9 with CT-cet). TC and IC were negative in 82 and 45% of cases, respectively; 15% sSCCs were both TC and IC positive. Progression-free survival (PFS) was longer in IC-positive cases (median 7.5 months vs. 2.1 in IC0, p = 0.02). No statistically significant differences were observed between PD-L1 expression and both overall survival and response rates. Conclusion: PD-L1 expression in microenvironment predicted better PFS. The combination of EGFR inhibitors and ICB could help deepening the knowledge about the interrelations between the EGFR and PD-1/PD-L1 pathways.
KW - Anti-epidermal growth factor receptor treatment
KW - Epidermal growth factor receptor
KW - Outcome
KW - PD-L1
KW - Skin squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85066884872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066884872&partnerID=8YFLogxK
U2 - 10.1159/000500246
DO - 10.1159/000500246
M3 - Article
C2 - 31112973
AN - SCOPUS:85066884872
VL - 97
SP - 112
EP - 118
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 2
ER -